Elevai Labs Beheer

Beheer criteriumcontroles 1/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Graydon Bensler

Algemeen directeur

US$110.0k

Totale compensatie

Percentage CEO-salaris	77.3%
Dienstverband CEO	less than a year
Eigendom CEO	1.7%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Graydon Bensler's beloning veranderd ten opzichte van Elevai Labs's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$5m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$110k	US$85k	-US$4m
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$4m
Mar 31 2023	n/a	n/a	-US$3m
Dec 31 2022	US$85k	US$85k	-US$2m

Compensatie versus markt: Graydon's total compensation ($USD110.00K) is below average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: Graydon's compensation has increased whilst the company is unprofitable.

CEO

Graydon Bensler (33 yo)

less than a year

Tenure

US$110,000

Compensatie

Mr. Graydon Bensler, CFA, serves as Chief Financial Officer, Secretary and Director of Elevai Labs Inc (formerly known as Reactive Medical Labs Inc.) and serves as it's CEO since June 21, 2024. (formerly,...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Graydon Bensler	CEO, CFO	no data	US$110.00k	1.7% $ 24.3k
Jeffrey Parry	Independent Director	1.4yrs	geen gegevens	0.084% $ 1.2k
Orian Shirihai	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Roger Fielding	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Juliana Daley	Independent Director	1.4yrs	geen gegevens	0.0024% $ 34.7
George Kovalyov	Independent Director	less than a year	geen gegevens	geen gegevens
Braeden Lichti	Non-Executive Chairman	less than a year	geen gegevens	3.35% $ 47.9k
Jordan Plews	Director	no data	US$200.00k	5.79% $ 82.6k
Eduardo Grunvald	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens

0.4yrs

Gemiddelde duur

39yo

Gemiddelde leeftijd

Ervaren bestuur: ELAB's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.

Elevai Labs Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Elevai Labs Inc. Announces the Appointment of Orian Shirihai to the Scientific Advisory Board of Elevai Biosciences Inc

High number of new and inexperienced directors

Elevai Labs Inc. Forms New Scientific Advisory Board

Elevai Labs Inc. Announces Executive Changes

Recent updates

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Topical Exosome Skincare Products with A Medical Aesthetic Energy Device

Elevai Labs Inc. has completed a Follow-on Equity Offering in the amount of $7.998032 million.

Elevai Labs Provides Nasdaq Stockholders Equity & Bid Price Listing Rule Update

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

New minor risk - Share price stability

Elevai Research Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.13 loss in 2Q 2023)

Elevai Labs Inc. Announces the Appointment of Orian Shirihai to the Scientific Advisory Board of Elevai Biosciences Inc

High number of new and inexperienced directors

Elevai Labs Inc. Forms New Scientific Advisory Board

Elevai Labs Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market, LLC

Elevai Labs Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market, LLC

First quarter 2024 earnings released: US$0.081 loss per share (vs US$0.11 loss in 1Q 2023)

Elevai Biosciences Inc. Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity

Elevai Labs Inc. Announces Executive Changes

New major risk - Market cap size

Full year 2023 earnings released: US$0.40 loss per share (vs US$0.19 loss in FY 2022)

Elevai Labs, Inc. Launches E-Commerce Portal

New major risk - Negative shareholders equity

Third quarter 2023 earnings released